• Login
    View Item 
    •   KovsieScholar Home
    • Electronic Theses and Dissertations
    • All Electronic Theses and Dissertations
    • View Item
    •   KovsieScholar Home
    • Electronic Theses and Dissertations
    • All Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Comparison of ADAMTS13 and Von Willebrand factor antigen levels and activities and plasminogen levels, in the currently available plasma products for the treatment of thrombotic thrombocytopenic purpura in South Africa

    Thumbnail
    View/Open
    VanMarleA.pdf (2.104Mb)
    Date
    2018
    Author
    Van Marle, Anneke
    Metadata
    Show full item record
    Abstract
    Thrombotic thrombocytopenic purpura results from a deficiency in the Von Willebrand factor cleaving protease, ADAMTS13. Treatment involves plasma exchange therapy with either fresh frozen plasma, cryosupernatant, or solvent/detergent-treated plasma (available locally as Bioplasma FDP®). The research aimed to generate in vitro data on these products, and to explore possible differences between them that may offer treatment advantages. Twenty samples per product were analysed for levels and activities of ADAMTS13 and Von Willebrand factor, and plasminogen levels (a proposed physiological backup system for ADAMTS13). Fresh frozen plasma and cryosupernatant samples were subanalysed according to ABO blood group. All samples had normal/high ADAMTS13 activity and plasminogen levels. Von Willebrand factor content was mostly normal for Bioplasma FDP®, typically deficient for cryosupernatant and mostly (unexpectedly) deficient for fresh frozen plasma. Depending on the parameter, Bioplasma FDP® was the most standardised (CV: 14.1% to 27.3%), whilst fresh frozen plasma showed great inter-individual variation (CV: 24.6% to 208.6%). Statistically significant differences were found across products (p values ≤ 0.0095) and ABO blood groups (p value: 0.0001). In conclusion, all three products can be used for treatment of thrombotic thrombocytopenic purpura. Product choice depends on the need for additional viral safety, costs, product availability and the perceived impact of within-product variations.
    URI
    http://hdl.handle.net/11660/10360
    Collections
    • All Electronic Theses and Dissertations
    • Masters Degrees (Haematology and Cell Biology)

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
     

     

    Browse

    All of KovsieScholarCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback